中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (5): 455-459.doi: 10.35541/cjd.20200179
李丹琪,楼雨晨,陶娟
收稿日期:
2020-02-26
修回日期:
2020-10-14
发布日期:
2022-04-29
通讯作者:
陶娟
E-mail:tjhappy@126.com
基金资助:
Li Danqi, Lou Yuchen, Tao Juan
Received:
2020-02-26
Revised:
2020-10-14
Published:
2022-04-29
Contact:
Tao Juan
E-mail:tjhappy@126.com
Supported by:
摘要: 【摘要】 大剂量静脉注射免疫球蛋白(IVIG)在部分难治性和危重皮肤病的治疗中疗效肯定,不良反应少。IgG的Fab段和Fc段可以通过结合各种自身抗原、自身抗体、补体等来介导特定的下游效应,以达到抗炎效果。该文综述IVIG的治疗机制,其在重症药疹、难治性皮肌炎和自身免疫性大疱病等重症皮肤病中的应用,以及特殊人群使用和不良反应等。
李丹琪 楼雨晨 陶娟. 大剂量静脉注射免疫球蛋白在重症皮肤病治疗中的应用进展[J]. 中华皮肤科杂志, 2022,55(5):455-459. doi:10.35541/cjd.20200179
Li Danqi, Lou Yuchen, Tao Juan. Application of high-dose intravenous immunoglobulin therapy in severe dermatoses[J]. Chinese Journal of Dermatology, 2022, 55(5): 455-459.doi:10.35541/cjd.20200179
[1] | Emre S. Intravenous immunoglobulin treatment: where do dermatologists stand?[J]. Dermatol Ther, 2019,32(3):e12854. doi: 10.1111/dth.12854. |
[2] | Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence[J]. J Allergy Clin Immunol, 2017,139(3S):S1⁃S46. doi: 10.1016/j.jaci. 2016.09.023. |
[3] | Liu P, Li L, Fan P, et al. High⁃dose of intravenous immunoglobulin modulates immune tolerance in premature infants[J]. BMC Pediatr, 2018,18(1):74. doi: 10.1186/s12887⁃018⁃1055⁃5. |
[4] | Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology⁃⁃mode of action and clinical efficacy[J]. Nat Rev Neurol, 2015,11(2):80⁃89. doi: 10.1038/nrneurol.2014.253. |
[5] | Mimouni D, Blank M, Payne AS, et al. Efficacy of intravenous immunoglobulin (IVIG) affinity⁃purified anti⁃desmoglein anti⁃idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris[J]. Clin Exp Immunol, 2010,162(3):543⁃549. doi: 10.1111/j.1365⁃2249.2010.04265.x. |
[6] | Bayry J, Kaveri SV. Kill ′Em All: Efgartigimod immunotherapy for autoimmune diseases[J]. Trends Pharmacol Sci, 2018,39(11):919⁃922. doi: 10.1016/j.tips.2018.08.004. |
[7] | Howard JF Jr, Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis[J]. Neurology, 2019,92(23):e2661⁃e2673. doi: 10.1212/WNL. 0000000000007600. |
[8] | Teeling JL, Jansen⁃Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia[J]. Blood, 2001,98(4):1095⁃1099. doi: 10. 1182/blood.v98.4.1095. |
[9] | Wang TT, Ravetch JV. Functional diversification of IgGs through Fc glycosylation[J]. J Clin Invest, 2019,129(9):3492⁃3498. doi: 10.1172/JCI130029. |
[10] | Pagan JD, Kitaoka M, Anthony RM. Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease[J]. Cell, 2018,172(3):564⁃577.e13. doi: 10.1016/j.cell.2017.11.041. |
[11] | Enk A, Hadaschik E, Eming R, et al. European Guidelines (S1) on the use of high⁃dose intravenous immunoglobulin in dermatology[J]. J Dtsch Dermatol Ges, 2017,15(2):228⁃241. doi: 10.1111/ddg.13013. |
[12] | Yang Y, Xu J, Li F, et al. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens⁃Johnson syndrome: a retrospective comparative study in China[J]. Int J Dermatol, 2009,48(10):1122⁃1128. doi: 10.1111/j.1365⁃4632.2009.04166.x. |
[13] | White KD, Abe R, Ardern⁃Jones M, et al. SJS/TEN 2017: Building multidisciplinary networks to drive science and translation[J]. J Allergy Clin Immunol Pract, 2018,6(1):38⁃69. doi: 10.1016/j.jaip.2017.11.023. |
[14] | Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens⁃Johnson syndrome and toxic epidermal necrolysis: a meta⁃analysis with meta⁃regression of observational studies[J]. Int J Dermatol, 2015,54(1):108⁃115. doi: 10.1111/ijd.12423. |
[15] | Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta⁃analysis[J]. Br J Dermatol, 2012,167(2):424⁃432. doi: 10.1111/j.1365⁃2133.2012.10965.x. |
[16] | 中国医师协会皮肤科医师分会变态反应性疾病专业委员会. 药物超敏反应综合征诊治专家共识[J]. 中华皮肤科杂志, 2018,51(11):787⁃790. doi: 10.3760/cma.j.issn.0412⁃4030.2018. 11.002. |
[17] | Shiohara T, Mizukawa Y. Drug⁃induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019[J]. Allergol Int, 2019,68(3):301⁃308. doi: 10.1016/j.alit.2019.03.006. |
[18] | 朱伟芳, 李炎冬, 斯子翔, 等. 静脉注射丙种球蛋白和糖皮质激素治疗药物超敏综合征的疗效观察[J]. 中华急诊医学杂志, 2013,22(9):1054⁃1056. doi: 10.3760/cma.j.issn.1671⁃0282. 2013.09.031. |
[19] | Galimberti F, Kooistra L, Li Y, et al. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis[J]. Clin Exp Dermatol, 2018,43(8):906⁃912. doi: 10.1111/ced. 13607. |
[20] | Sunderkötter C, Nast A, Worm M, et al. Guidelines on dermatomyositis⁃⁃excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology[J]. J Dtsch Dermatol Ges, 2016,14(3):321⁃338. doi: 10.1111/ddg.12909. |
[21] | 中国医疗保健国际交流促进会皮肤科分会. 寻常型天疱疮诊断和治疗专家建议(2020)[J]. 中华皮肤科杂志, 2020,53(1):1⁃7. doi: 10.35541/cjd.20190703. |
[22] | Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts[J]. J Am Acad Dermatol, 2020,82(3):575⁃585.e1. doi: 10.1016/ j.jaad.2018.02.021. |
[23] | Gürcan HM, Jeph S, Ahmed AR. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety[J]. Am J Clin Dermatol, 2010,11(5):315⁃326. doi: 10.2165/11533290⁃00000 0000⁃00000. |
[24] | Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists′ guidelines for the management of pemphigus vulgaris 2017[J]. Br J Dermatol, 2017,177(5):1170⁃1201. doi: 10.1111/bjd.15930. |
[25] | Ahmed AR, Kaveri S. Reversing autoimmunity combination of rituximab and intravenous immunoglobulin[J]. Front Immunol, 2018,9:1189. doi: 10.3389/fimmu.2018.01189. |
[26] | Ahmed AR, Shetty S, Kaveri S, et al. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: a retrospective study with a 6⁃year follow⁃up[J]. J Am Acad Dermatol, 2016,74(4):700⁃708.e3. doi: 10.1016/j.jaad.2015.11.030. |
[27] | Ahmed AR, Nguyen T, Kaveri S, et al. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow⁃up[J]. Int Immunopharmacol, 2016,34:25⁃31. doi: 10.1016/j.intimp.2016.02.013. |
[28] | 中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南[J]. 中华内科杂志, 2020,59(3):172⁃185. doi: 10.3760/cma.j.issn.0578⁃1426.2020.03.002. |
[29] | Nieto⁃Aristizábal I, Martínez T, Urbano MA, et al. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a single⁃center experience with 63 patients[J]. Lupus, 2019,28(13):1566⁃1570. doi: 10.1177/0961203319883 680. |
[30] | Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases[J]. Rheumatology (Oxford), 2015,54(3):383⁃391. doi: 10.1093/rheumatology/keu429. |
[31] | Wong PH, White KM. Impact of Immunoglobulin therapy in pediatric disease: a review of immune mechanisms[J]. Clin Rev Allergy Immunol, 2016,51(3):303⁃314. doi: 10.1007/s12016⁃015⁃8499⁃2. |
[32] | Jee SJ, Kim JH, Baek HS, et al. Long⁃term efficacy of intravenous immunoglobulin therapy for moderate to severe childhood atopic dermatitis[J]. Allergy Asthma Immunol Res, 2011,3(2):89⁃95. doi: 10.4168/aair.2011.3.2.89. |
[33] | Rademaker M, Agnew K, Andrews M, et al. Managing atopic dermatitis with systemic therapies in adults and adolescents: an Australian/New Zealand narrative[J]. Australas J Dermatol, 2020,61(1):9⁃22. doi: 10.1111/ajd.13141. |
[34] | Tekin B, Yücelten AD. Infantile bullous pemphigoid treated using intravenous immunoglobulin: case report and review of the literature[J]. Pediatr Dermatol, 2015,32(5):723⁃726. doi: 10. 1111/pde.12635. |
[35] | Kushner CJ, Concha J, Werth VP. Treatment of autoimmune bullous disorders in pregnancy[J]. Am J Clin Dermatol, 2018,19(3):391⁃403. doi: 10.1007/s40257⁃018⁃0342⁃0. |
[36] | Ahmed AR, Gürcan HM. Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris[J]. J Eur Acad Dermatol Venereol, 2011,25(9):1073⁃1079. doi: 10.1111/j.1468⁃3083.2010.03925.x. |
[37] | Guo Y, Tian X, Wang X, et al. Adverse effects of immunoglobulin therapy[J]. Front Immunol, 2018,9:1299. doi: 10.3389/fimmu. 2018.01299. |
[38] | Hoffmann J, Enk AH. High⁃Dose Intravenous immunoglobulin in skin autoimmune disease[J]. Front Immunol, 2019,10:1090. doi: 10.3389/fimmu.2019.01090. |
[1] | 中国医师协会皮肤科医师分会自身免疫病专业委员会 . 【开放获取】环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022, 55(6): 471-479. |
[2] | 闪莹 左亚刚. 自身免疫性疱病与银屑病的相关性[J]. 中华皮肤科杂志, 2022, 55(5): 452-455. |
[3] | 张国毅, 龚向东, 朱伯堃, 柳传霞, 景玲华, 徐金玉. 2019年中国医学科学院皮肤病医院门诊病种分析[J]. 中华皮肤科杂志, 2022, 55(2): 150-152. |
[4] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会. 自身免疫性表皮下大疱病诊疗共识(2022)[J]. 中华皮肤科杂志, 2022, 55(1): 1-11. |
[5] | 姜沛彧 张嘉文 刘子菁 王小燕 刘韵祎 刘乙萱 许阳. 光生物调节的基本原理及其在皮肤科的应用[J]. 中华皮肤科杂志, 2022, 55(1): 84-87. |
[6] | 龙海 蒋丽 邱月棨 姚南 刘力聪 谢昱明 熊峰 谭思齐 匡琪琪 尤睿璇 柴可 罗鑫 龙浩君 忻悦 郭子瑜 王佳琪 谭怡忻 张庆 张桂英 李亚萍 苏玉文 肖嵘 陆前进, . 皮肤科病房危重症1 057例临床分析[J]. 中华皮肤科杂志, 2021, 54(9): 790-797. |
[7] | 胡枫 陈柳青 王巍 郑芳. COVID-19流行期间武汉某医院皮肤科门诊患者流行病学特点及疾病谱分析[J]. 中华皮肤科杂志, 2021, 54(8): 719-722. |
[8] | 应洁雅 相文忠 宋秀祖. 代谢综合征与皮肤病[J]. 中华皮肤科杂志, 2021, 54(7): 642-645. |
[9] | 中国医师协会皮肤科医师分会自身免疫病专业委员会. 甲氨蝶呤治疗免疫相关性皮肤病专家共识[J]. 中华皮肤科杂志, 2021, 54(5): 382-390. |
[10] | 康莉 刘艳 郑云燕 鞠梅 张亚美 毕志刚 芦桂青. 马血清破伤风抗毒素与马破伤风免疫球蛋白F(ab′)2引起的皮肤迟发型变态反应临床分析[J]. 中华皮肤科杂志, 2021, 54(3): 226-228. |
[11] | 叶瑞贤 薛如君 梁景耀 刘焕颜 熊绮颖 董良娇 张锡宝. microRNA在炎症性皮肤病中作用的研究进展[J]. 中华皮肤科杂志, 2021, 54(2): 178-182. |
[12] | 刘沛 石磊 王秀丽. 皮肤疾病光动力治疗的光源和照光参数选择[J]. 中华皮肤科杂志, 2021, 54(11): 1015-1018. |
[13] | 朱蓓蓓 李婧 黄慧瑶 李宁 刘利军 张丽华 宦静 倪琪 侯伟 刘毅 杨雪源. 2020年中国皮肤病药物临床试验分析[J]. 中华皮肤科杂志, 2021, 54(11): 1001-1004. |
[14] | 郑玉灿 孔桂萍 金玉 李玫. FAM111B基因突变致遗传性纤维性皮肤异色病伴跟腱挛缩、肌病和肺纤维化一例[J]. 中华皮肤科杂志, 2021, 54(11): 973-977. |
[15] | 陈伟 谢恒 李利. 胞外囊泡在皮肤科的研究进展和应用前景[J]. 中华皮肤科杂志, 2021, 54(10): 910-914. |
|